TCF1+PD-1+肿瘤浸润淋巴细胞预测非小细胞肺癌免疫检查点抑制剂治疗后的良好反应与生存延长
本研究在234例RNA-seq队列和116例免疫组化队列的非小细胞肺癌患者中,探讨TCF1+PD-1+肿瘤浸润淋巴细胞对免疫检查点抑制剂疗效的预测价值。结果显示,应答者的TCF1+PD-1+ TIL数量及PD-L1肿瘤比例评分显著高于无应答者,高TCF1+PD-1+ TIL数量与更长的无进展生存和总生存显著相关,多因素分析中可独立预测更好的PFS和OS。
要点
- 应答者的TCF1+PD-1+ TIL数量显著高于无应答者。
- 高TCF1+PD-1+ TIL数量与免疫治疗后更长的PFS和OS显著相关。
- 多因素分析显示TCF1+PD-1+ TIL可独立预测更好的PFS和OS。
核心结论
- TCF1+PD-1+ TIL代表祖细胞样耗竭T细胞,可预测NSCLC患者ICI治疗后的更好应答和生存。
研究设计与样本
- 纳入两个接受靶向PD-1/PD-L1通路ICI治疗的NSCLC患者队列。
- RNA-seq队列:对234例患者免疫治疗前获取的NSCLC组织进行RNA-seq。
- 免疫组化队列:对另116例患者切除的肿瘤组织进行TCF1和PD-1双重免疫染色及其他免疫标志物单染。
主要发现
- RNA-seq队列中,应答者较无应答者富集耗竭T细胞和祖细胞样耗竭T细胞基因集。
- 较大的耗竭T细胞比例和增加的祖细胞样耗竭T细胞基因集与更好的PFS显著相关。
- 免疫组化队列中,应答者的TCF1+PD-1+ TIL数量和PD-L1肿瘤比例评分显著高于无应答者。
- 高数量TCF1+PD-1+ TIL与ICI治疗后的PFS和OS均显著相关。
- 多因素分析显示TCF1+PD-1+ TIL可独立预测更好的PFS和OS。
临床怎么用
- 作者认为TCF1+PD-1+ TIL可能是NSCLC中ICI治疗有用的预测性生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: T-cell factor 1 (TCF1)+Programmed cell death-1 (PD-1)+ tumour-infiltrating lymphocytes (TILs) are a recently defined subset of exhausted T-cells (Texh-cells) that exhibit a progenitor phenotype. They have been associated with a response to immune checkpoint inhibitor (ICI) therapy in murine tumour models and in patients with malignant melanoma. We investigated the significance of TCF1+PD-1+ TILs as a predictive biomarker for ICI therapy response in non-small-cell lung cancer (NSCLC). METHODS: Two different cohorts of NSCLC patients treated with ICI targeting the PD-1/PD-L1 pathway were included. RNA-seq was performed using NSCLC tissues obtained from 234 patients prior to immunotherapy (RNA-seq cohort). Double immunostaining of TCF1 and PD-1 and single immunostaining of other immunologic markers were performed in resected tumour tissues from another 116 patients (immunohistochemistry cohort). RESULTS: In the RNA-seq cohort, both Texh-cell and progenitor Texh-cell gene sets were enriched in responders compared with non-responders. Larger Texh-cell fractions and increased progenitor Texh-cell gene sets were significantly associated with better progression-free survival (PFS). In the immunohistochemistry cohort, the TCF1+PD-1+ TIL number and PD-L1 tumour proportion score were significantly higher in responders than in non-responders. A high number of TCF1+PD-1+ TILs was significantly associated with both PFS and overall survival (OS) after ICI therapy, and it independently predicted a better PFS and OS according to multivariate analysis. CONCLUSION: TCF1+PD-1+ TILs, representing progenitor Texh-cells, predict both better response and survival in NSCLC patients after ICI therapy. Thus, they may be a useful predictive biomarker for ICI therapy in NSCLC.
引用
- Koh J, Kim S, Woo YD, et al. TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. Eur J Cancer. 2022. PMID: 35970031. doi:10.1016/j.ejca.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。